Quest Diagnostics Inc vs iShares MSCI Canada (TSX) — how do they compare? Quest Diagnostics Inc trades at $205.71 (market cap $22.80B), while iShares MSCI Canada (TSX) trades at $59.32. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares MSCI Canada (TSX) pays none, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | EWC | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $59.46 |
52-Week Low | $166.42 | $45.86 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EWC trades at $58.73, up 0.14% with a bullish technical signal supported by moving averages. The stock shows strong momentum indicators but lacks available fundamental data for P/E, P/S, and profitability metrics. Recent corporate actions include a $0.28 dividend scheduled for June 2026, while Canadian economic news highlights trade surplus expansion and nuclear energy development.
Outlook remains cautiously optimistic given technical strength and positive Canadian economic trends, though limited fundamental visibility and USMCA trade agreement uncertainties present key risks for investors monitoring this US-listed Canadian-focused ETF.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →